TNFRSF4 antibody
Quick Overview for TNFRSF4 antibody (ABIN206653)
Target
See all TNFRSF4 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Specificity
- Recognizes feline CD134, otherwise known as OX40, a 43kD type I membrane protein and member of the tumor necrosis factor receptor superfamily, expressed predominantly by CD4+ activated T cells, and a key regulator of T cell-dependent immune responses. CD134 has been identified as the receptor for the OX40 ligand, CD252, expressed by activated B cells, acting as a co-stimulatory signal for the stimulation and secretion of immunoglobulins. CD134 has also been identified as a binding receptor for Feline Immunodeficiency Virus (FIV), acting along with CXC chemokine receptor 4 (CXCR4) to facilitate the entry of the virus into CD4+ primary target cells.
-
No Cross-Reactivity
- Mouse (Murine)
-
Purification
- Protein A purified
-
Immunogen
-
CHO-derived feline CD134-Fc fusion protein.
Type of Immunogen: Fusion protein -
Isotype
- IgG1
-
-
-
-
Application Notes
-
Approved: Flo, WB (1 μg/mL)
Usage: Flow Cytometry: Use 10 μL of the suggested working dilution to label 1x10^6 cells in 100 μL. Method sheets are available on request. Western Blot: LS-C44970 detects a band of approximately 43kD. -
Comment
-
Target Species of Antibody: Cat
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- Lot specific
-
Buffer
- PBS, 0.09 % sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
-
- TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))
-
Alternative Name
- TNFRSF4 / CD134 / OX40
-
Background
-
Name/Gene ID: TNFRSF4
Family: TNF Receptor
Synonyms: TNFRSF4, ACT35 antigen, ATC35 antigen, CD134, ACT35, OX40, OX40 antigen, OX40L receptor, OX40 homologue, CD134 antigen, OX40 cell surface antigen, TXGP1L -
Gene ID
- 7293
-
UniProt
- P43489
-
Pathways
- Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints
Target
-